Zydus Cadila signs deal with US-based Prolong

Zydus Cadila has signed an agreement with US-based Prolong Pharmaceuticals to develop a therapeutic protein, PEG-EPO, for treatment of severe anaemia.

As per the agreement, both companies will utilise Prolong's differentiated PEGylation technology to make PEG-EPO.

Severe anaemia is a condition where the hemoglobin (Hb) level or number of circulating red blood cells (RBCs) is significantly reduced. This is common in chronic renal failure (CRF), cancer patients undergoing chemotherapy, chronic inflammatory diseases, heart failure, and critically-ill patients.